Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you for that Cabinet Guy!
Yes, you are quite right, all of this is speculation and also I intend my posts to be for discussion purposes only. In general I'm known to make conservative estimates in most financial matters as I don't wish to over state anything. I am very conservative in most of my views.
The Buy Out could easily occur at 3X that amount, i.e. $3.75/share @ $14 Billion or even much more, but again it all depends on the offer elements that Koos has in mind, and obviously no one can read his mind.
Well Said!
..and that's my exact case in point in my posts today!
Koos is moving at the speed of light to get ALL of RGBP's Patents re-activated and also getting Pink Current, and the ONLY reason I can think of why he's moving with such speed and finesse is he has several offers on this company and ALL of these elements need to be taken care of for him to proceed.
It's important to note that Koos has dropped on the average of three (3) SEC filings PER WEEK dating back to the beginning of this year and this in and of itself revels the direction he's going in COMBINED with the 8K he filed on 4/27/21 that protects against a Hostile Take Over.
Be well and prosper...
Well Said African Trader!
100% CORRECT!
That is how Valuation was determined by Gilead Sciences when they bought Kite for $11.9 Billion in 2017 and that was based on the only Patent Kite had at that time that was mRNA based AND it had not yet been FDA approved for entering clinical trials.
This should speak volumes to all share holders of RGBP due having 24 Patents that includes mRNA Vaccine Biotechnology especially in light of the advancements in mRNA Vaccines that have gone global for Covid-19 via Pfizer, Moderna, etc. This is now the BIGGEST MARKET in the entire Pharmaceutical Industry and everyone wants a piece of that Trillion Dollar Global Market Share.
There are people that think a Buy Out of RGBP will be based solely on its current pps. This is an absurd & ridiculous notion.
Candidate Drug Patent Valuation is always based on the merit, validity, and therapeutic application of the science AND the projected Market Valuation.Then typically there's a premium added to the current PPS ALL of which was exactly the case when Gilead bought Kite. These elements are not different when buy out value determination is made for ANY Pharmaceutical Company.
It will be NO DIFFERENT when RGBP is bought out IF that happens, and that is a very high probability! Thus the reason for Dr. Koos filing that 8K on 4/27/21, i.e. his's NOT going to allow RGBP to be bought out from under him without a say in the purchase price and because of that 8K his voice in fact will be the only one that determines what offers will and won't be accept. This point should cause lights to go on in everyone's thinking. This man is highly intelligent and experienced in this industry and that 8K protects his "golden goose" and guarantees him to get the PRICE he wants for this company and it's going to be a whopping price tag!...again IF a Buy Out occurs!
Just imagine what the Buy Out offer would be on RGBP due to holding not ONE (1) but TWENTY FOUR (24) Disruptive Biotechnology Patents that includes mRNA vaccine biotechnology for treating pancreatic & colon cancer. The Combined Value of RGBP's Patents are absolutely astronomical.
In closing, let me say this, IF I was on the Advisory Board of any of the Big Pharmas I listed, I will tell the CEO that he/she would be insane if they didn't immediately BUY/Acquire RGBP, and here' the reality; these CEO's already know that if they don't buy RGBP another Big Pharma will and if that happens they will have missed an opportunity to expand their therapeutic portfolio, in particular in the area of mRNA based vaccines, AND a chance to OWN THE SCIENCE that went into all 24 of RGBP's Patents that are ALL Candidate Drug Patents.
It's going to be very interesting to see what happens in the very near future once we go Pink Current and Koos accomplishes renewing ALL of RGBP's Patents.
My personal take on this and prediction is there's going to be a BIDDING WAR over RGBP, so anyone holding shares in this company I would advise to hold tight those shares and those who haven't opened a position in RGBP has better do that soon or they will miss a once in a lifetime opportunity at wealth building.
Be well and prosper...
Top 5 Big Pharma "Pick List" That Might Acquire RGBP
I will begin this discussion with the direct quote from Dr. Koos's 8-K filing on 4/27/21 where he specifically states on Page 2 the following:
https://www.otcmarkets.com/filing/conv_pdf?id=14894907&guid=xlC1knmJNkY37yh
Quote
"To the extent that the Non-Convertible Series NC Preferred Stock may have Anti-Takeover Effects, Regen believes that the ability of Regen to issue shares with such voting power will encourage persons seeking to ACQUIRE Regen to negotiate directly with the Board of Directors enabling the Board of Directors to consider the proposed transaction in a manner that best serves the stockholders’ interests."
The language Koos is using here is in reference to himself who due to the issuing of Preferred Stock arrangements that give him sole Voting Power and therefore exclusive control over RGBP as the head of the Board of Directors. What this means is that any Big Pharma seeking to acquire RGBP can NOT go around him to the share holders to negotiate offers to acquire the company which the share holders as a whole would decide, thus a "Hostile Take Over." With this arrangement only Koos can decide what offers to accept or not accept on his terms alone thereby putting him in full control.
My Top 5 Pick List of Potential Acquiring Big Pharmas
I have listed these in the order of the highest probability from the top down and have provided a brief discussion on each of why I believe these Big Pharmas would be interested in acquiring RGBP. This is based on my professional opinion as a clinical trials physician with over 30+ Years history as a Principal Investigator who designed and managed the conduct of patient based clinical trials for Big Pharma's FDA approved Candidate Drug Patents.
All of these companies I listed have one thing in common, they are among the Pharmas that have positioned themselves in the mRNA Vaccine Space that includes Cancer Vaccines.
I have provided a link at the end of this discussion that shows the Top Cancer mRNA Vaccine Pharmaceutical Companies in the world at the present time.
#1
Gilead Sciences
Market Cap: $91.2 Billion
PPS: $ 72.80
As we all know Gilead acquired Kite Pharma in 2017 for $11.9 Billion Cash to add mRNA Vaccine Biotechnology to their therapeutic market portfolio. This is a classic move than many Big Pharms are known to make to expand their footprint in the pharmaceutical market place.
This single move in fact positioned this company as a "first comer" in this transformative area of "Novel Therapeutic BioTechnology" that has the capacity to reshape Modern Medicine relative to the treatment of serious diseases that historically respond poorly to conventional therapies. For those of you who aren't familiar with this term it is in reference pioneering development of sophisticated or enhanced new drug therapies that have the capacity to exponentially increase treatment efficiency with dramatically improved clinical out comes and quality of life.
I am introducing you here to concepts from world of the Big Pharma industry and revealing what they ALL seek to achieve at any financial cost or otherwise and the fact that Gilead was willing to pay Kite Pharma nearly $12 Billion cash to acquire their mRNA Vaccine Patent for treating various cancers should cause a blaring light to come on in your perception of how Big Pharms think and what they're willing to do to stay out in front of the competition, which is a extraordinarily fierce competition. Just think, Gilead took the chance to acquire that Patent for BILLIONS when little was known in 2017 about mRNA Biotechnology, not knowing IF it would pan out in clinical trials and reach Market, but yet they shelled out that kind of money with insight from their scientific leadership that it was a high probability that it would, and it did, but yet they took the gamble anyway and it PAID OFF IN SPADES and dramatically strengthened their market position and made them a serious player in the mRNA Vaccine niche market based on that single acquisition of Kite.
My perception is Gilead would definitely be interested in acquiring RGBP in order to not only expand their foot print in the mRNA Vaccine Biotechnology space but also other areas of Novel Therapeutics based on the 20+ Candidate Drug Patents RGBP has in their portfolio.
IMO if Gilead acquires RGBP that would very possibly put them on track to be named among the Top 10 Pharmaceutical Companies in the world based on Annual Revenues. Currently their annual revenues are between $24 to $26 Billion as of 2020-21. They will need to double their revenues to make it into the Top Ten, and my perception is by them controlling more Patents in the mRNA vaccine space and also expanding their Biotechnology by developing RGBP's other 23 Patents they could very possibly accomplish this, but first they need to control more of the rapidly expanding mRNA Vaccine Market and acquiring RGBP is the "fast track" for that to happen. What the average person doesn't realize is this market is expanding exponentially in the wake of the Covid-19 mRNA vaccine coming to Market."
Some of you may recall that in one of my previous posts I characterized the Big Pharma industry as "cut throat", "vicious" meaning Big Pharma companies will do whatever is necessary to gain great control of market share in their respective niche markets, and that motive is by any means necessary and money is no obstacle. The single best example of this is Gilead acquiring Kite in 2017 shelling out $12 Billion for Kite's one (1) mRNA Vaccine Patent when little was know about it, and if a Big Pharma doesn't have billions in cash to do this, they are known to form partnerships with other Big Pharmas to acquire Patents then share in the development cost and market revenues. i.e. having half of a cake is better than having none at all, and this is literally how Big Pharmas think.
IMO, there will be several Big Pharmas in line, if not already, seeking to acquire RGBP and Koss is possibly right now in negotiations for the best deal for the sale of this company to the benefit of both shareholders and ultimately himself.
#2
Precigen
Market Cap:$1.2 Billion
PPS: $5.60
As most here know the CEO of Precigen, Helen Sabzevari, was previously on RGBP's scientific advisory board and the company is in the cancer-oncology mRNA vaccine space the same as RGBP. IMO, it would behoove Precigen to acquire RGBP for the same reasons I described for Gilead.
Remember, it's all about control of Market share based on independently developed and/or acquired Biotechnology and those Patents coming to Market.
This move for Precigen would be a no brainer IF they're interested in strengthening their Market position and simultaneously not allowing RGBP's Patents to be acquire by one of their competitors. That would be extremely foolish if they allow that to happen and Koos has possibly already advised them of this.
#3
Pfizer
Market Cap: $275 Billion
PPS: $49.25
We know that RGBP has had a prior collaborative arrangement with a Pfizer scientist in the development of their biotechnology. We also know that Pfizer is now a world leader in the mRNA vaccine space relative to Covid-19. Common sense dictates that they would seek to diversify their footprint into the cancer-oncology mRNA vaccine space to capture a substantial share of that Market which of course is a Multi-Billion dollar market no different than the Covid-19 mRNA vaccine space. They will need RGBP's current FDA approved Patent that's about to enter clinical trials to fast track themselves in that direction. This is based on basic common sense and they have the cash to acquire RGBP easily.
#4
Moderna
Market Cap: $154 Billion
PPS: $382
This Pharma like Pfizer has had great success in the mRNA Covid vaccine space and like Pfizer they need to move swiftly to diversify their Market position by expanding it to include an mRNA Vaccine for treating various forms of cancer. My understanding is that both Pfizer & Moderna are already moving in that direction and by acquiring RGBP, Moderna would benefit the most by needing to expand their therapeutic footprint thereby diversifying their market position and them moving into the oncology-immunology space with an mRNA cancer vaccine by acquiring RGBP would put them on the fast track in that direction AND they would benefit the most as a young company to own ALL 24 of RGBP's Patents that they can systematically place into their clinical trials pipeline.
With their amazing success in the mRNA Covid Vaccine market caused a dramatic rise in their pps from the $20 range last year to hitting nearly $500 this year, they definitely have the financial resources to acquire RGBP. Acquiring RGBP would be fundamentally transformative to this company and make them a major contender in the mRNA vaccine space with market diversification that ALL Big Pharmas seek.
#5
BioNTech
Market Cap: $85 Billion
PPS: $350
BioNTech is a German based Pharma trading on NASDAQ under the symbol BNTX. It was founded in 2008 and is considered to be a "New Technologies Next Generation Immunotherapy Company" developing novel therapies for various cancers and other serious diseases.
The Company has a wide range of discovery therapeutic platforms for the rapid development of novel biopharmaceutical Patents. It has a broad portfolio of oncology patent drug candidates that include individualized cancer type specific mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific checkpoint immuno-modulators, targeted cancer antibodies, and small molecules. Their approach to immuno-oncology drug discover is profound, highly advanced, rapid, and wide range.
The company has broad expertise in mRNA vaccine development and in-house manufacturing capacity. BioNTech has a myriad of Big Pharma collaborators for developing multiple mRNA vaccine candidates that includes targeting wide range of infectious diseases alongside its diverse oncology pipeline. It's Big Pharma collaborator/partnerships include Sanofi, Bayer, Genentech, Roche, Regeneron, and Pfizer.
This company is a prime example of how Big Pharmas aggressively form partnership arrangements with other Big Pharma players in order to fast track their scientific discoveries relative to developing novel candidate drug patents and leverage gaining market share much faster than if they were to go it alone.
This key point in and of itself makes RGBP a prime candidate for acquisition by this company, not only to gain important scientific I.P. insights that can further their own candidate drug development prospects, but also ADD to placing drug patents instantly into their clinical trials pipeline that RGBP developed. Not only this, they have an extensive clinical trials pipeline in house that affords seamless communication, logistics, FDA data/results reporting, and cost control.
Here is the link to their company website
https://investors.biontech.de/news-releases/news-release-details/biontech-announces-first-patient-dosed-phase-2-clinical-trial
Link to the TOP mRNA Cancer Vaccines Pharmas in the world
https://www.ventureradar.com/keyword/Cancer%20Vaccines
It is my hope that the information I provided in my discussion serves many of you in your decision making about investing in RGBP and also builds confidence that you are in the right place at the right time.
Just know that the Patents RGBP has are absolutely worth Billions and there are many Big Pharmas who would substantially benefit from acquiring them not only to gain scientific insight into their own drug development processes, but also afford them with the luxrey of placing many of RBGP drug Patents immediately into their clinical trials pipeline which is the "fast track" to any of them gaining Market share, keeping in mind that each of these Patents cost Millions to develop, required thousands of hours of scientific bench work, and many years or decades to develop.
Lastly, if a Buy Out/Acquisition occurs it will NOT be based alone on RGBP's current pps. That is not reality. It will be based on the full perceived market value of this company that includes ALL 24 of its Patents, keeping in mind that any Patent can be updated and modified based on additional scientific discovery with information that was not previously available when the Patent was originally filed.
I believe if RGBP is acquired it will be at or near $1.25/share and with this last discussion it's important to keep in mind that the value of anything is based on what someone is willing to pay for it!.
CASE IN POINT!! > Keep in mind that the perceived value of Kite Pharma at the time Gilead Sciences purchased this company in 2017 for nearly $12 Billion Cash, was based largely on the mRNA cancer vaccine candidate drug Patent they developed relative to its future global market potential, plus a premium on the prevailing pps at the time of acquisition, and again this was at a time when little was known about mRNA Biotechnology unlike today now everyone in the Pharmaceutical Industry knows about it and is highly motivated to carve out a piece of that Market in order to remain competitive in the rapidly advancing pharmaceutical landscape that's on the brink of radical transformation in medical therapeutics that will define the future or "New Age" of Medicine. i.e. cures for cancer, aids/hiv, and in some cases the elimination of life threatening diseases altogether via Gene Editing.
Disclaimer: All the above is my personal opinion only that's based on common sense.
All feedback welcome...pro or con.
Be well and prosper...
EXCELLENT POST- Very Insightful
Most investors here may not be aware of this but the Pharmaceutical Industry as a whole is highly collaborative with other Pharmas BioPharmas within their respective niche markets, and they also do this to expand their niche market.
This explains why a Muti-Billion Dollar Market Cap Big Pharma like Gilead Sciences acquired the small Private Kite BioPharma for $11.9 Billion Cash just to own the only Patent Kite had at the time in 2017, which was (is) an mRNA based Patent for treating various cancers. By doing this Gilead Sciences instantly expanded their niche market.
But other Big Pharmas may acquire or merge with other Pharmas BioPhamas just to obtain the science behind their Patents with the motive that it provides them with the missing pieces of the puzzle for developing their own Patents. If you understand this you have grasped a very big reality of what drives many if not most Big Pharmas.
Case in point, have you ever asked yourself why was a leading scientist at Pfizer, Dr. Rohit Duggal, recruited by RGBP to sit on their Scientific Advisory Board for supporting advancements in development of therapeutics? Dr. Duggal has 17 years experience in drug discovery based at Pfizer as a leader of their cancer stem cell group. He has led development of drug patents that entered clinical trials having experience in translating small molecules into clinical candidates.
This is just one example of what I'm referring to, but Big Pharmas are also know to engage in direct joint venture collaboration that can and does at times led to Merger-Acquisitions.
I have no question in my mind that RGBP is on the same track for what happened to Kite Pharma being bought by Gilead Sciences in 2017 that made them an instant player in the mRNA Vaccine Biotechnology space, and them buying Kite Pharma is what opened the door for that to happen.
Essentially Gilead "bought" that Biotechnology that dramatically strengthened their Market position, and no doubt have expanded on it since then. They wanted to break into the mRNA Vaccine Niche Market that they saw coming on the horizon back in 2017 and they were RIGHT! Now today, it's FRONT CENTER STAGE!
Gilead by acquiring Kite positioned themselves in front of a Multi-Trillion Dollar Global Trend that's absolutely going re-define the Practice of Modern Medicine and that acquisition will prove to make them vast fortunes far beyond what they already have, and any Big Pharma that acquires RGBP will accomplish the same thing and they better HURRY!
So the "take away" here is RGBP is DEFINITELY a Merger-Acquisition/Buy Out candidate like Kite Pharma in 2017, and it wouldn't surprise me at all if Gilead Sciences is a suitor not only for RGBP's mRNA Patent Biotechnology that's near entering clinical trials for cancer treatment, but also to own ALL 24 of RGBP's Patents. This move would dramatically strengthen Gilead's Market position (or any Big Pharma) like non other and this is classic of HOW Big Pharmas go about staying ahead of the competition, i.e. BUY THE BIOTECHNOLOGY then engineer it to the Hilt!
With this I just introduced many of you to the insider World of the Pharmaceutical Industry and how they think and operate.
Later today I will Post my Top 5 Picks of Big Pharmas that might acquire RGBP and I'll give the reasons why....Gilead Sciences is one of them!
Have a great weekend now that we're UP another 17.3% @ 0.04.
Oh, and don't worry about the wicked Naked Short Selling MMs, they will definitely get BLOWN AWAY Post-Pink Current when Massive Buying sets in World Wide! Just look at what Pink Limited did! This definitely was responsible for an increase in buy volume yesterday but not like what's about to happen.
It has already been proven dozens of times MMs can't hold the PPS down when large buy volumes occur and a preview of that we just saw yesterday when we hit 0.04 with nearly a Quarter Billion in Trading Volume to the tune of nearly $10 Million Dollars! This was a great preview of what's coming, only the beginning!
Personally I'm looking for $1.25 short term and $2+ EOY if not Buy Out first!
Stay tuned for my Top 5 Big Pharma "Buy Out" Picks later today!
Be well and prosper...
That's EXACTLY What Happened Just Before ENZC Made Its Run to ~$1
History is repeating itself but in a MUCH GREATER way for RGBP!
I will post later today a list of Big Pharmas that might Acquire RGBP (if that happens) and I'll provide the reasons why?
There are at least five (5) I have identified that make sense.
Be well and prosper and may ALL of you become financially wealthy on this Play!
It's All Good NOW! UP from Here!!
Still heavily LOADING just like I did with ENZC on it's run to $1.00.
Made 7 figures on that one within 20 weeks!
ENZC's PPS at the time of its run in February started around the same PPS as RGBP is today!
Post Pink current within 19 trading days ENZC's PPS EXPLODED and it is highly likely RGBP will follow the same pattern Post Pink Current and MUCH HIGHER for reason ENZC was A LOT LESS developed then compared to RGBP today, in fact no comparison not even close!
Also, notice how with Pink Limited the PPS has already started to climb in anticipation of going Pink Current!
Be well and prosper...
Closed UP Nearly 30%
Now THAT's a Game Changer!
Looks like everyone got wind of Pink Limited TODAY and know that Pink Current is STRAIGHT AHEAD!
We could go PINK CURRENT ANY DAY EVEN LATER TODAY OR TOMORROW!!
....then WORLD WIDE BUYING will set it rapidly and cause the PPS to Sky Rocket!
My Prediction is RGBP will easily surpass ENZC's run in February and it wouldn't surprise me at all if our first major run is to $1.25 to $1.50, keeping in mind that ENZC's run hit nearly $1.00 six months ago and had A LOT LESS going for it then, compared to what RGBP has TODAY!!! In fact no comparison!
Here's a recap of why RGBP should surpass ENZC's run:
ENZC had:
#1 (1) Patent only
#2 No FDA approval
#3 No licensing arrangements
#4 No partnerships
#5 No catalysts
#6 No PR releases
#7 No prospect of revenue (due to #2 & #3)
#8 No suggestion of Buy Out by CEO
RGBP has:
#1 20+ Patents worth $BILLIONS
#2 Licensing of (1) Patent with (2) INDs (New Drug Applications) for treating pancreatic & colon cancer by mRNA Vaccine-"The Future of Medicine"
#3 Recent FDA Patent Approval for Clinical Trials.
#4 Partnership: Received $1.1 Million up front payment from Oncology Pharma for Patent Licensing and is NOW positioned to receive Quarterly Revenues for 15 YEARS! (Totally unheard of for ANY OTC Stock)
#5 Going Pink Current IMMINENT ANY DAY = Instant buying capacity World Wide!
#6 CEO suggests Buy Out by filing an 8K on 4/27/21 to protect against a Hostile Take Over that specifically states "parties interested to ACQUIRE must negotiate directly."
I'm fully expecting RGBP to run North of $1.00 short term Post Pink Current, and $2+ by end of year if not higher!
Then there's the very real specter of a Big Pharma Buy Out or Merger Acquisition that most everyone here already knows about based on Koos filing that 8K on 4/27/21 that protects against a Hostile Take Over!
Based on what RGBP has today, I view it as a "Hybrid" NASDAQ stock based on its extensive portfolio of Disruptive Biotechnology Patents some of which are mRNA based which very clearly is the Future of Medicine, recent FDA Patent approval, AND being positioned for Quarterly Revenues. It simply doesn't get any better than this on the OTC.
Look for my next Post on the Top 5 possible Buy Out-Merger Acquisition Big Pharma players that I believe may be the suitors to acquire RGBP in the days ahead!
Be well and prosper...
Pink Limited as of TODAY!!
Pink Current NEXT!
https://www.otcmarkets.com/stock/RGBP/disclosure
Koos takin' care of plenty business!
Be well and prosper...
Another 10-Q Drops Today!
https://www.otcmarkets.com/stock/RGBP/disclosure
Any ideas on how many more SEC filings need to drop before going Pink Current??
Be well and prosper...
Sounds Good To Me!
Cheers!
AMEN!
RGBP FOR THE WIN!!
BUY OUT HIGHLY LIKELY!
HA! HA! ANOTHER 10Q Drops & UP 20%
https://www.otcmarkets.com/stock/RGBP/disclosure
Looks like ONE more to GO!
Then Pink Current...WORLD WIDE MASSIVE BUYING!!!
Are ALL 24 of RGBP's Patents a "Shell Game?"
2). ..also, is the Patent that's currently licensed to Oncology Pharma for TWO (2) IND's for treating pancreatic & colon cancer with up front payment to RGBP for over $1 Million Dollars in Stock, is that also a "Sell Game??"
3). Is Koos reactivating all or most of RGBP's expired Patents that he listed in a recent SEC filing, that cost thousands of dollars, is that also a "shell game"
..please explain in detail.
Yes, Definitely!
Be well and prosper...
Here's Reason #4
#4- It's going to take hundreds of millions of dollars to put the re-activated Patents into FDA Approved Clinical Trials.
Here's a link that provides an estimate for this.
https://www.jhsph.edu/news/news-releases/2018/cost-of-clinical-trials-for-new-drug-FDA-approval-are-fraction-of-total-tab.html
The average or "median" cost in 2015-2016 was $16 Million per clinical trial. Today it would be much higher.
Also, this article points out that for clinical trials that involve examining "a drug's ability to prevent a clinically meaningful outcome..", the median cost is much higher, i.e. $65 Million per trial, and again that was back in 2015-2016.
So yes as I said, to put those re-activated Patents into clinical trials is going to cost a absolute FORTUNE....ALL CASH!!
Big Pharma Buy Out is the only thing that makes sense, IMO.
Opinion Only...
Be well and prosper.
NOT BAD!! NOT BAD AT ALL!!!
Another 15.29% GAIN today and holding! (according to eTrade)
What that means is we're UP 102.2% from 7/29/21 to TODAY!
That's in ONLY 8 Trading Days!
Holding GAINS DAILY!!!
IMO, the BUYING has begun early!! Likely Retailers beginning to flood in before Pink Current to lock in present low pps.
7/29/21
Close
0.0134
Today 8/9/21
Close
0.0279
eTrade
Remember MMs can't handle high volume buying, and today was only moderate range volume!
Now just imagine what's going to happen when we go PINK CURRENT with WORLD-WIDE BUYING! That's going to give the MMs a NERVOUS BREAKDOWN!!!
Cheers!
Be well and prosper...
Great Article: Biotechs In Cancer Research Being Acquired at Massive Valuations!
https://www.prnewswire.com/news-releases/biotech-companies-focused-on-cancer-research-are-being-acquired-at-massive-valuations-300961695.html
Yes, that's quite correct, and this will likely happen to RGBP which I recently predicted an 80% probability.
One major example of that is Kite Pharma being acquired by Gilead Sciences in 2017 for $11.9 Billion to control their only Patent based on mRNA Biotechnology for treating various cancers.
Gilead paid a premium on top of Kite Pharma's Share price for many multiples MORE than it was trading for at the time of acquisition, AND their Patent had NOT yet been approved by the FDA for clinical trials.
Just goes to show you where we are today in RGBP that also has mRNA biotechnology and is in the same cancer treatment space as Kite.
Be well and prosper...
A Physician's Perspective of RGBP
As a medical doctor, I am trained to objectively look at the clinical presentation of patients over my 30+ year career and make treatment decision that at times are a matter of life and death.
My treatment decision(s), like any doctor, can either position a patient on the road to recovery or lead to their demise. Importantly, all such decisions are based on known objective FACTS not only of a patient's medical history and clinical condition, but also on the selected pharmaceuticals for treatment. If my decisions are WRONG the patient can either get worse or DIE!
A crucial area of objective clinical assessment of patients includes the thought process of what has been proven to have a positive outcome on other patients with a similar medical history, clinical condition, and applied therapeutics.
The "take away" here is simple: FACTS MATTER!!!
Although this is not a forum for clinical evaluation of patients and treatment decisions, nevertheless objective observations based on FACTS are in play about RGBP that includes comparisons to a similar stock, ENZC.
Their similarities?? Empirically, both are Miro-Caps and both are developmental stage BioPharmas that have candidate drug Patents endeavoring to enter clinical trials for treatment evaluation of very serious medical conditions. If successful, those Patents will come to Market as Pharmaceuticals that will have a market capacity in the $Billions!
However there's a great objective separation between the two companies relative to their patent portfolio and progress:
Here's a re-cap of that comparison relative to ENZC's run to nearly $1.00 in February:
ENZC had:
#1 (1) Patent only
#2 No FDA approval
#3 No licensing arrangements
#4 No partnerships
#5 No catalysts
#6 No PR releases
#7 No prospect of revenue (due to #2 & #3)
#8 No suggestion of Buy Out by CEO
RGBP today has:
#1 24 Patents each worth $BILLIONS
#2 Licensing of (1) Patent with (2) INDs for treating pancreatic & colon cancer by mRNA Biotechnology that very clearly is The Future of Medicine
#3 FDA Approval for entering Clinical Trials is Imminent due to licensing arrangements with Oncology Pharma; a CRO that places drug patents into clinical trial venues and works proactively with the FDA for this to occur. It is very unlikely Oncology Pharma would have purchased licensing rights to that Patent if they didn't perceive it would have a very high probability of getting approved by the FDA for clinical trials.
#4 Partnership: Received up front payment from Oncology Pharma for Patent Licensing and is NOW positioned to receive Quarterly Revenues for 15 YEARS!
#5 Going Pink Current within days = Instant buying capacity on dozens of brokerage platforms World-Wide!
#6 CEO suggests Buy Out by filing an 8K on 4/27/21 to protect against a Hostile Take Over during negotiations that specifically states "negotiations must be made direct" (in reference to himself)
These are the OBJECTIVE COMPARATIVE FACTS!
Now, based on these facts, it would be reasonable to anticipate that RGBP Post-Pink Current will either match or surpass ENZC's run back in February when it hit $0.95 only 19 trading days after it went Pink Current.
To assume otherwise would require ignoring the significant fundamental differences between there two BioPharmas!
Again, FACTS MATTER!!!
I believe my comparative assessment of these two companies is reasonable, objective, and predictable based on known facts.
Lastly, Post September 28, 2021, the OTC will have a far different playing field due to the elimination of all Non-SEC compliant stocks.
This will result in a significant reduction in available stocks to invest in by the thousands.
Of the remaining stocks, the question needs to be asked how many of them will continue to be highly speculative, i.e. no business operations, no developed products or services, no operating capital, no partnerships, no prospect of revenue, etc.
I believe I just described 95% of The New OTC. As a result it would be reasonable to assume that world wide investor dollars are going to naturally flow into stocks that have lower risk with actual products, established business operations, are advanced in their development, and have a high Market Capacity like RGBP!
All of the above is a Personal Opinion only, but one that makes common sense.
I invited all feedback both pro & con.
Be well and prosper...
1000% CORRECT!
You NAILED it real good!
Thanks!
Be well and prosper...
Excellent Post!
Thank you-
Be well and prosper...
Excellent Read!
Thank you for nicely laying out all the concise details that make it easy to follow and understand.
You provided an AMAZING comprehensive post on this important subject!
AAAA+++
May I suggest that you re-post that on Reddit!
Be well and prosper...
Thank you much for your valuable feedback!
Much appreciated!
Now I know!
Thanks
Be well and prosper..
Yes, I will respond sometime today before end of day, Saturday 8/7
The OTC Short List
https://www.otcshortreport.com/company/GRST
Just noticed that yesterday and the day before GRST was Shorted at the Level of 58 & 59 percent respectively.
On July 22nd it was as high as 86%.
Based on this, it appears the "Shorting Trend" seems to be going down from July 23rd to now, with a low on August 4th of 37.7%
IMO, this might mean a REVERSAL in Shorting is beginning and if so, the PPS should begin rising.
Any comments about this?
Thanks
Be well and prosper...
Provide the Direct Source Link...
....confirming your statement "It's been confirmed factual."
If you can't OR ignore this request it means your statement is conjecture.
Not Bad! An Additional 13.6% Gain!
...on above average volume with net accumulation all day!
Looks good to me!
Now all that's needed are the additional filings to drop and it's all good!
A LOT of profit taking today, scaredy cats jumping ship psyched out by the MMs who they handed their shares over to!
Barchart says STRONG BUY 100%
https://www.barchart.com/stocks/quotes/RGBP/overview
UP from here!!
Be well and prosper..
UP 20%.38 & Rising - Steady Accumulation!
Definitely under consistent Accumulation & RISING by the minute!
https://ih.advfn.com/stock-market/USOTC/regen-biopharma-pk-RGBP/trades
$0.257
Very good sign!
I may be right, the MM's BUYING REVERSAL may have already begun!
If that's the case the PPS will RISE DAILY from consolidating at higher trading ranges!
Cheers!
RGBP Rising On Moderate Volume Holding a 6% Gain Over Yesterday!
....AND it's under accumulation to boot!
https://ih.advfn.com/stock-market/USOTC/regen-biopharma-pk-RGBP/trades
Let's see if we hit 0.03 today!
Be well and prosper...
Holding Gains From Yesterday and UP Today!
UP 7.5% so far over yesterday!
Good Sign!
It appears the MM's BUYING REVERSAL may be in progress!
All we need now is Pink Current with World-Wide Buying!
Be well and prosper...
Another Great Post 29 YEARINVESTOR!
Confirmed, (3) 10Qs dropped yesterday and (1) the day prior!
That's (4) 10Qs dropped within the past 48 hours!
https://www.otcmarkets.com/stock/RGBP/disclosure
Talk about High Speed Diligence! Personally, I've never seen anything like this before!
And just who was it that said Koos isn't going to come through?? HA!
Be well and prosper...
19% Gains Holding On Nearly Quarter Billion Volume!!!
Not bad for STARTERS!!
Just imagine when World-Wide BUY VOLUME sets in Post-Pink Current!
GREAT START!
Amazing Volume - 216 MILLION And Rising!!!
That's nearly 3X Average Volume on a 21% gain with 2 hours to go!
We may HIT a Quarter Billion In Volume TODAY!!
Not bad....for starters!
A very positive sign for what's to come!
Be well and prosper..
The MM's BUYING REVERSAL May Have Begun Early!
If Volume is sustained and Gains Hold, it means we're off to the races!
Watch for my next Post later today on Big Pharma Buy-Out/Merger Acquisition Predictions....it may surprise you!
Be well and prosper...
I Believe I Know!
...he's preparing the Company for a Buy Out OR Merger-Acquisition!
I base this on:
#1. his aggressive consistent actions to bring the company SEC Compliant which has direct major implications for a Buy Out - Merger Acquisition relative to the acquiring Company.
#2. Reviving RGBP's expired Patents, which also has direct major implications for a Buy Out - Merger Acquisition relative to the acquiring Company.
#3. The 8K Koos filed on 4/27/21 that prevents a Hostile Take Over during negotiations. (did he do that because he had nothing else better to do OR he had no real concern of that happening??) I doubt that very seriously!. The logical reason is to PREVENT the company from being bought out from under him, i.e. the acquiring company going around him having a say in negotiations as the CEO, which is exactly what happens in a Hostile Take Over!!!
#4. Placing those re-activated Patents into clinical trials is going to cost a fortune, each one of them, which most Big Pharmas can easily afford due to having a Multi-Billion Dollar Market Cap with serious on going revenues;the very thing RGBP does NOT have! Then there's the man power logistics of it all which is extremely time consuming, expensive, and demanding on a daily continuous basis.
In order for those Patents to fly, it's going to take a Big Pharma to make it happen the way it should for reason they have the infrastructure, expertise, vast man power, and cash on demand deep pockets to fuel any number of clinical trials simultaneously with no problem whatsoever. No need to seek loans, engage in stock dilution, etc. ALL HARD CASH!!
#5. Very importantly, the man is in his mid-60s sailing toward 70. It's likely someone his age who has worked his entire life and has made major contributions to the Medical Sciences that at this point he would want to fold and enjoy the rest of his life doing whatever he feels like doing with no encumbrances. This MIGHT be the ONLY chance he has to live out the remaining "QUALITY OF LIFE" years he has left.
ALL these factors COMBINED from my perspective spells Buy-Out or Merger Acquisition which I'm now giving an 80% probability! I could be wrong but everything described here "strongly" points to this.
Another possibility is IF there's a Merger-Acquisition he might be on the Board of Directors of the Acquiring Company in an advisory capacity only but NOT required to be involved in the daily operations. This would position him for Semi-Retirement where he's still free to spend his time the way he wants and live off the fruits of his life's labor without any encumbrances.
PERSONAL OPINION ONLY!!!....BUT one that makes sense!
All feedback welcome pro & con.
Be well and prosper...
Thanks for Your Feedback!
Much appreciated!
Almost there!
Thanks A Million$$$
Almost there!!!
Another 10K Dropped Today!
https://www.otcmarkets.com/stock/RGBP/disclosure
Does anyone wish to comment on what else has to drop to bring us Current?
Thanks
Be well and prosper
Well Said on ALL Three (3) Points!
...in particular #3.
I have also always maintained that Koos, being in his mid 70s sailing toward 80, is ready to fold and move on with his life and live off the fruits of his labor doing things in his senior years he would like to do, and this "deal" represents the Grand Finale of his decades long career, i.e. "Retirement."
It fits and it makes total sense!
Thank you for your post.
Be well and prosper..
That's Certainly Consistent With the 4/27/21 8K Filing!
https://www.otcmarkets.com/filing/conv_pdf?id=14894907&guid=p3z1kFzzo5ePhbh
...in particular this paragraph:
"To the extent that the Non-Convertible Series NC Preferred Stock may have Anti-Takeover Effects, Regen believes that the ability of Regen to issue shares with such voting power will encourage persons seeking to ACQUIRE Regen to negotiate directly with the Board of Directors enabling the Board of Directors to consider the proposed transaction in a manner that best serves the stockholders’interests."
Notice the proactive context using the plural subject tense.
With this, your Post is "spot on", i.e. both "Tentative" & "Multi-Party."
Other words, Koos very possibly is wheeling and dealing a Buy Out OR Merger-Acquisition, only question is...with who? The probability of this is very high IMO, if not, then one has to ask themselves what's the point of this 8K??
This 8K would definitely be consistent with what I've always maintained; WHY would he file this unless he has the intention to SELL to the highest bidder??...in the best interest of the shareholders. And this extends to him rushing to pull everything together with re-activating RGBP's expired Patents and hiring a professional auditor to get all the filings SEC current. All of this seems to fit "hand in glove."
Seems logical to me, but who am I to judge?
The 20/20 here is it really doesn't take a rocket scientist to decipher the proactive intent of this 8K.
One thing's for certain however....WE ARE ABOUT TO FIND OUT REAL SOON!
Be well and prosper...